REVIEW

Drug eluting stents: are human and animal studies comparable?

R Virmani¹, F D Kolodgie¹, A Farb¹, A Lafont²

¹ Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington DC, USA
² Hôpital Européen Georges Pompidou, INSERM E00-16, Université, Paris V, France

Correspondence to:
Correspondence to:
Dr Renu Virmani, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Washington DC 20306-6000, USA;
virmani{at}afip.osd.mil

Animal models of stenting probably predict human responses as the stages of healing are remarkably similar. What is characteristically different is the temporal response to healing, which is substantially prolonged in humans. The prevention of restenosis in recent clinical trials of drug eluting stents may represent a near absent or incomplete phase of intimal healing. Continued long term follow up of patients with drug eluting stents for major adverse cardiac events and angiographic restenosis is therefore imperative.

Keywords: stent; drug eluting stent; coronary artery disease

Abbreviations: ASPECT, Asian paclitaxel eluting stent clinical trial; ELUTES, evaluation of paclitaxel-eluting stent; IVUS, intravascular ultrasound; MACE, major adverse cardiac event; RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent in treatment of de novo native coronary artery lesions; SIRIUS, sirolimus eluting stent

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ormiston, J. A., Webster, M. W.I., Schwartz, R. S., Gladding, P., Stewart, J. T., Kay, I. P., Ruygrok, P. N., Hatrick, R. (2009). Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent: Traditional Pre-Clinical Safety End Points Failed to Predict 6-Month Clinical Angiographic Results. J Am Coll Cardiol Intv 2: 1017-1024 [Abstract] [Full Text]  
• Vorpahl, M., Finn, A. V., Nakano, M., Virmani, R. (2009). Do We Really Understand Pimecrolimus?. J Am Coll Cardiol Intv 2: 1025-1027 [Full Text]  
• Kallmes, D.F., Ding, Y.H., Dai, D., Kadirvel, R., Lewis, D.A., Cloft, H.J. (2009). A Second-Generation, Endoluminal, Flow-Disrupting Device for Treatment of Saccular Aneurysms. Am. J. Neuroradiol. 30: 1153-1158 [Abstract] [Full Text]  
• Chandrashekhar, Y., Kern, M. J., Narula, J. (2009). Devices, biology, imaging, and the regulatory processes.... J Am Coll Cardiol Img 2: 670-673 [Full Text]  
• Suzuki, Y., Yeung, A. C., Ikeno, F. (2009). The Pre-Clinical Animal Model in the Translational Research of Interventional Cardiology. J Am Coll Cardiol Intv 2: 373-383 [Abstract] [Full Text]  
• Lee, K.-J., Hinek, A., Chaturvedi, R. R., Almeida, C. L., Honjo, O., Koren, G., Benson, L. N. (2009). Rapamycin-Eluting Stents in the Arterial Duct: Experimental Observations in the Pig Model. Circulation 119: 2078-2085 [Abstract] [Full Text]  
• Finn, A. V., Nakazawa, G., Kolodgie, F. D., Virmani, R. (2009). Temporal Course of Neointimal Formation After Drug-Eluting Stent Placement: Is Our Understanding of Restenosis Changing?. J Am Coll Cardiol Intv 2: 300-302 [Full Text]  
• Sarembock, I. J. (2008). From Systemic Shotgun to Site-Specific Nanoparticle-Targeted Delivery: A New Paradigm for Drug Delivery. Arterioscler. Thromb. Vasc. Bio. 28: 1879-1881 [Full Text]  
• Joner, M., Morimoto, K., Kasukawa, H., Steigerwald, K., Merl, S., Nakazawa, G., John, M. C., Finn, A. V., Acampado, E., Kolodgie, F. D., Gold, H. K., Virmani, R. (2008). Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma. Arterioscler. Thromb. Vasc. Bio. 28: 1960-1966 [Abstract] [Full Text]  
• Schwartz, R. S., Edelman, E., Virmani, R., Carter, A., Granada, J. F., Kaluza, G. L., Chronos, N. A.F., Robinson, K. A., Waksman, R., Weinberger, J., Wilson, G. J., Wilensky, R. L. (2008). Drug-Eluting Stents in Preclinical Studies: Updated Consensus Recommendations for Preclinical Evaluation. Circ Cardiovasc Interv 1: 143-153 [Abstract] [Full Text]  
• Joner, M., Nakazawa, G., Finn, A. V., Quee, S. C., Coleman, L., Acampado, E., Wilson, P. S., Skorija, K., Cheng, Q., Xu, X., Gold, H. K., Kolodgie, F. D., Virmani, R. (2008). Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents. J Am Coll Cardiol 52: 333-342 [Abstract] [Full Text]  
• Jabara, R., Chronos, N., Conway, D., Molema, W., Robinson, K. (2008). Evaluation of a novel slow-release Paclitaxel-eluting stent with a bioabsorbable polymeric surface coating.. J Am Coll Cardiol Intv 1: 81-87 [Abstract] [Full Text]  
• Wilson, G. J., Polovick, J. E., Huibregtse, B. A., Poff, B. C. (2007). Overlapping paclitaxel-eluting stents: Long-term effects in a porcine coronary artery model. Cardiovasc Res 76: 361-372 [Abstract] [Full Text]  
• Pires, N. M M, Eefting, D., de Vries, M. R, Quax, P. H A, Jukema, J W. (2007). Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 93: 922-927 [Abstract] [Full Text]  
• Ribichini, F., Joner, M., Ferrero, V., Finn, A. V., Crimins, J., Nakazawa, G., Acampado, E., Kolodgie, F. D., Vassanelli, C., Virmani, R. (2007). Effects of Oral Prednisone After Stenting in a Rabbit Model of Established Atherosclerosis. J Am Coll Cardiol 50: 176-185 [Abstract] [Full Text]  
• Finn, A. V., Nakazawa, G., Joner, M., Kolodgie, F. D., Mont, E. K., Gold, H. K., Virmani, R. (2007). Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing. Arterioscler. Thromb. Vasc. Bio. 27: 1500-1510 [Abstract] [Full Text]  
• Luthra, S., Tatoulis, J., Warren, R. J. (2007). Drug-Eluting Stent-Induced Left Anterior Descending Coronary Artery Aneurysm: Repair by Pericardial Patch--Where Are We Headed?. Ann. Thorac. Surg. 83: 1530-1532 [Abstract] [Full Text]  
• Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., Virmani, R. (2006). Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk. J Am Coll Cardiol 48: 193-202 [Abstract] [Full Text]  
• Blindt, R., Vogt, F., Astafieva, I., Fach, C., Hristov, M., Krott, N., Seitz, B., Kapurniotu, A., Kwok, C., Dewor, M., Bosserhoff, A.-K., Bernhagen, J., Hanrath, P., Hoffmann, R., Weber, C. (2006). A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor Cells. J Am Coll Cardiol 47: 1786-1795 [Abstract] [Full Text]  
• Anis, R R, Karsch, K R (2006). The future of drug eluting stents. Heart 92: 585-588 [Abstract] [Full Text]  
• Mitra, A K, Agrawal, D K (2006). In stent restenosis: bane of the stent era.. J. Clin. Pathol. 59: 232-239 [Abstract] [Full Text]  
• Jaschke, B., Michaelis, C., Milz, S., Vogeser, M., Mund, T., Hengst, L., Kastrati, A., Schomig, A., Wessely, R. (2005). Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 68: 483-492 [Abstract] [Full Text]  
• LaDisa, J. F. Jr., Olson, Lars. E., Molthen, R. C., Hettrick, D. A., Pratt, P. F., Hardel, M. D., Kersten, J. R., Warltier, D. C., Pagel, P. S. (2005). Alterations in wall shear stress predict sites of neointimal hyperplasia after stent implantation in rabbit iliac arteries. Am. J. Physiol. Heart Circ. Physiol. 288: H2465-H2475 [Abstract] [Full Text]  
• Wessely, R., Hausleiter, J., Michaelis, C., Jaschke, B., Vogeser, M., Milz, S., Behnisch, B., Schratzenstaller, T., Renke-Gluszko, M., Stover, M., Wintermantel, E., Kastrati, A., Schomig, A. (2005). Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating. Arterioscler. Thromb. Vasc. Bio. 25: 748-753 [Abstract] [Full Text]  
• Rotmans, J. I., Pattynama, P. M.T., Verhagen, H. J.M., Hino, I., Velema, E., Pasterkamp, G., Stroes, E. S.G. (2005). Sirolimus-Eluting Stents to Abolish Intimal Hyperplasia and Improve Flow in Porcine Arteriovenous Grafts: A 4-Week Follow-Up Study. Circulation 111: 1537-1542 [Abstract] [Full Text]  
• Murphy, G. J, Ascione, R., Angelini, G. D (2004). Coronary artery bypass grafting on the beating heart: surgical revascularization for the next decade?. Eur Heart J 25: 2077-2085 [Abstract] [Full Text]  
• Schwartz, R. S., Edelman, E. R., For the Consensus Committee, , Carter, A., Chronos, N. A., Rogers, C., Robinson, K. A., Waksman, R., Machan, L., Weinberger, J., Wilensky, R. L., Goode, J. L., Hottenstein, O.D., Zuckerman, B. D., Virmani, R. (2004). Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications: Recommendations From an Expert Consensus Group. Circulation 110: 2498-2505 [Full Text]  
• Schwartz, R. S., Chronos, N. A., Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 44: 1373-1385 [Abstract] [Full Text]  
• Farb, A., Kolodgie, F. D., Hwang, J.-Y., Burke, A. P., Tefera, K., Weber, D. K., Wight, T. N., Virmani, R. (2004). Extracellular Matrix Changes in Stented Human Coronary Arteries. Circulation 110: 940-947 [Abstract] [Full Text]  
• Vogt, F., Stein, A., Rettemeier, G., Krott, N., Hoffmann, R., Dahl, J. v., Bosserhoff, A.-K., Michaeli, W., Hanrath, P., Weber, C., Blindt, R. (2004). Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25: 1330-1340 [Abstract] [Full Text]  
• Chong, P. H, Cheng, J. W. (2004). Early Experiences and Clinical Implications of Drug-Eluting Stents: Part 1. The Annals of Pharmacotherapy 38: 661-669 [Abstract] [Full Text]  
• Bhatia, V, Bhatia, R, Dhindsa, M (2004). Drug-eluting stents: new era and new concerns. Postgrad. Med. J. 80: 13-18 [Abstract] [Full Text]